Literature DB >> 16991120

Increased plasma DNA integrity index in head and neck cancer patients.

Wei-Wen Jiang1, Marianna Zahurak, David Goldenberg, Yelena Milman, Hannah Lui Park, William H Westra, Wayne Koch, David Sidransky, Joseph Califano.   

Abstract

Analysis of the length of circulating DNA in plasma has been reported as a marker for solid tumor detection. We assessed the sensitivity and specificity of increased plasma DNA length to identify patients with head and neck squamous cell carcinoma (HNSCC) and monitor posttreatment disease status. Fifty-eight HNSCC patients with paired pre- and postoperative plasma and 47 plasma samples from control subjects were analyzed using quantitative PCR to determine plasma DNA integrity index. We found that the mean DNA integrity index was significantly greater in the plasma from HNSCC patients, 0.24 (95% CI: 0.11, 0.38), when compared to plasma from the control subjects, -2.24 (95% CI: -2.92, -1.56), p < 0.0001 using multivariate analysis. The optimal sensitivity (the value for which sensitivity equals specificity) was found at a plasma DNA integrity index of 0.82: sensitivity, 84.5%; specificity, 83%. However, there was no significant difference noted between pre- and postoperative DNA integrity index in plasma samples from HNSCC patients. This study shows that DNA integrity index in the plasma of the patients with HNSCC is increased in comparison with that in the plasma from non-HNSCC control subjects. Lack of normalization of plasma DNA integrity index after surgical resection implies the persistence of a population of cells with an altered pattern of DNA degradation despite removal of malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16991120     DOI: 10.1002/ijc.22250

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.

Authors:  Paola Ulivi; Rosella Silvestrini
Journal:  Cell Oncol (Dordr)       Date:  2013-11-01       Impact factor: 6.730

2.  Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood.

Authors:  Lan Lin; Jeannette Y Lee; Lawrence D Kaplan; Bruce J Dezube; Ariela Noy; Susan E Krown; Alexandra M Levine; Yanxing Yu; Gary S Hayward; Richard F Ambinder
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

3.  Characterization of cell-free circulating DNA in plasma in patients with prostate cancer.

Authors:  Pâmela Oliveira Delgado; Beatriz Costa A Alves; Flávia de Sousa Gehrke; Renata Kelly Kuniyoshi; Marcelo Langer Wroclavski; Auro Del Giglio; Fernando Luiz Affonso Fonseca
Journal:  Tumour Biol       Date:  2012-12-27

4.  Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer.

Authors:  T B Hao; W Shi; X J Shen; J Qi; X H Wu; Y Wu; Y Y Tang; S Q Ju
Journal:  Br J Cancer       Date:  2014-08-26       Impact factor: 7.640

5.  Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy.

Authors:  Feng Zhu; Jing Ma; Dongdong Ru; Ningning Wu; Yunhua Zhang; Huiyuan Li; Xiaoli Liu; Jianfeng Li; Huiling Zhang; Yue Xu; Jiangman Zhao; Hui Tang; Yusheng Wang; Weihua Fu
Journal:  J Oncol       Date:  2021-05-26       Impact factor: 4.375

6.  Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer.

Authors:  Peter Brian Gahan
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

7.  Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.

Authors:  Krishna B Sriram; Vandana Relan; Belinda E Clarke; Edwina E Duhig; Morgan N Windsor; Kevin S Matar; Rishendran Naidoo; Linda Passmore; Elizabeth McCaul; Deborah Courtney; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  BMC Cancer       Date:  2012-09-25       Impact factor: 4.430

8.  Multiparametric analysis of cell-free DNA in melanoma patients.

Authors:  Francesca Salvianti; Pamela Pinzani; Paolo Verderio; Chiara Maura Ciniselli; Daniela Massi; Vincenzo De Giorgi; Marta Grazzini; Mario Pazzagli; Claudio Orlando
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

Review 9.  The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.

Authors:  Yahya I Elshimali; Husseina Khaddour; Marianna Sarkissyan; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

10.  Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology.

Authors:  José A González-Masiá; Damián García-Olmo; Dolores C García-Olmo
Journal:  Onco Targets Ther       Date:  2013-07-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.